hxdbzxy
hxdbzxy / iStockphoto.com
15 March 2018Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
18 July 2017   The European Commission has called out Teva over anti-competitive behaviour centring on a pay-for-delay drug deal.
Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.

More on this story

Big Pharma
18 July 2017   The European Commission has called out Teva over anti-competitive behaviour centring on a pay-for-delay drug deal.
Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.

More on this story

Big Pharma
18 July 2017   The European Commission has called out Teva over anti-competitive behaviour centring on a pay-for-delay drug deal.
Europe
13 March 2018   The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.